Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

Abstract: The present invention relates to human skin-derived fibroblasts having a tendon regeneration effect and a pharmaceutical composition for regenerating and treating a tendon, and the allogeneic skin-derived fibroblasts may have similar cell morphology to tenocytes, have a high expression level of vimentin, which is a fibroblast marker, express a large amount of extracellular matrix proteins, TGF-?, and increase collagen synthesis by acting on an ERK signaling mechanism, thereby effectively regenerating an injured tendon.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

Abstract: The present invention relates to a composition for skin improvement containing at least one chemokine selected from the group consisting of B lymphocyte chemoattractant (BLC), also known as C-X-C motif ligand 13 (CXCL13), and thymus-expressed chemokine (TECK), also known as C-C motif ligand 25 (CCL25), as an active ingredient. Since the BLC (CXCL13) and TECK (CCL25) of the present invention increase the expression of proliferation marker Ki-67 and collagen IV, which are proteins concerning skin regeneration and skin elasticity, and exhibit excellent melanin-reducing and wound-healing effects and the ability to induce chemotaxis of keratinocytes, they can be applied in a cosmetic composition for skin improvement.

Abstract: The present invention relates to a cosmetic composition having a cotton candy form. The cosmetic composition in a cotton candy form is prepared by freeze-drying an algin aqueous solution, and thus can be prepared through a simple process, has excellent moldability, and can stably contain, even at room temperature, a protein such as a cytokine, a peptide, and the like, which have particular storage requirements.

Abstract: The present invention includes a method for preparing a three-dimensionally cultured skin model comprising dermis and epidermis, which comprises: a step of preparing the dermis using a composition comprising murine fibroblasts; and a combination of native collagen and atelocollagen; and a step of forming the epidermis using keratinocytes. Also, the present invention relates to a three-dimensionally cultured skin model which comprises: a dermis prepared by a composition comprising murine fibroblasts, native collagen, or a combination of native collagen and atelocollagen; and epidermis formed from keratinocytes.

Abstract: The present invention relates to a composition for skin improvement containing at least one chemokine selected from the group consisting of B lymphocyte chemoattractant (BLC), also known as C-X-C motif ligand 13 (CXCL13), and thymus-expressed chemokine (TECK), also known as C-C motif ligand 25 (CCL25), as an active ingredient. Since the BLC (CXCL13) and TECK (CCL25) of the present invention increase the expression of proliferation marker Ki-67 and collagen IV, which are proteins concerning skin regeneration and skin elasticity, and exhibit excellent melanin-reducing and wound-healing effects and the ability to induce chemotaxis of keratinocytes, they can be applied in a cosmetic composition for skin improvement.

Abstract: The present invention relates to: biomarker proteins for diagnosing scars; a composition for diagnosing scars by using the same; a biochip for diagnosing scars; and a method for obtaining information on the scars. Proteins identified by the present invention can be applied as biomarkers for screening scars. A patient with keloid scars can be diagnosed by using the biomarker. In addition, the biomarker can be used for treating a patient with keloid scars.

Abstract: The present invention relates to a method for preparing a three-dimensionally cultured skin model comprising dermis and epidermis, which comprises: a step of preparing the dermis using a composition comprising murine fibroblasts; and native collagen or a combination of native collagen and atelocollagen; and a step of forming the epidermis using keratinocytes. Also, the present invention relates to a three-dimensionally cultured skin model which comprises: a dermis prepared by a composition comprising murine fibroblasts, native collagen, or a combination of native collagen and atelocollagen; and epidermis formed from keratinocytes.

Abstract: Provided is a tissue regeneration material release-inducing cell therapeutic composition including a medium for cryopreservation of an animal cell which contains a protein, a sugar, a buffer, and a basal medium and does not contain DMSO, glycerol, and serum. The cell therapeutic composition of the present invention is characterized in that both an animal cell and the medium for cryopreservation of an animal cell have tissue regeneration efficacy, as a tissue regeneration accelerating material within cells is released into the medium for cryopreservation through freezing and thawing processes of the cells. In addition, the cell therapeutic composition of the present invention may be directly cryopreserved in a vial, ampoule or pre-filled syringe, thereby being highly convenient for use, and does not use a cryopreservative agent and serum and thus may be directly applied to a lesion without a separate washing process.

Abstract: There is provided a method for stably preserving cells and valuable materials included in the cells at room temperature by lyophilizing the cells. When the cells are lyophilized using a lyoprotectant, damage to the structure of the cells which may otherwise occur during a freezing process can be prevented, the lyophilized cells can be stored at room temperature, and the valuable material included in the cells may maintain the functions thereof at room temperature.

Abstract: There is provided a dressing for treating a wound. The dressing for healing a wound can be useful in maintaining a moisture environment at a wound site using a biocompatible polymer scaffold, and effectively promoting healing of a wound by various growth factors secreted by skin cells or stem cells attached to the biocompatible polymer scaffold as well.